Sg2, a Vizient company, has published a white paper on the effects of the rapid increase in cardiovascular disease and related challenge of timely patient access to lifesaving interventions such as transcatheter aortic valve replacement (TAVR) procedures. The paper, “The Rising Tide of Cardiovascular Disease: A Looming Crisis for Cardiovascular Intervention Resources” notes an 8% increase in demand for inpatient procedures and a 25% increase for outpatient procedures over the next 10 years.

“We are seeing significant growth in heart valve diseases such as aortic stenosis due to underlying risk factors such as hypertension, high cholesterol, obesity and diabetes, as well as other cardiovascular diseases such as congestive heart failure,” said Joshua Aaker, PhD, director, Sg2. “Hospitals struggling to provide timely access to interventions such as TAVR, will likely have sicker patients who need more intensive services and longer hospital stays.”

To address this issue, Sg2 recommends health systems focus on short-term care redesign and long-term investment plans for catheterization labs, care teams, resources and patient beds to match forecasted demand. The paper includes multiple short- and long-term strategies including:

• Optimizing existing capacity via flexible scheduling protocols and identifying low-risk procedures that can be shifted to noninvasive approaches.
• Adopting AI-enabled tools for patient management to help identify high-risk patients, assess social determinants of health (SDOH) and ensure the efficient provision of guideline-directed medical therapy.
• Collaborating with home health agencies to enable same-day discharge for certain cardiovascular procedures to reduce bed-day utilization.
• Leveraging remote patient monitoring for managing chronic conditions such as heart failure, hypertension and post-TAVR follow-up to optimize workforce efficiency.
• Acquiring or building additional ambulatory surgery centers or procedural suites to alleviate capacity constraints.

“By strategically optimizing existing resources and making the necessary investments in people, technology and infrastructure, health systems can improve their cardiovascular service lines, enhance patient care and position themselves to meet the increasing need for complex, resource-intensive procedures like TAVR,” said Aaker.

Read The Rising Tide of Cardiovascular Disease.

About Sg2

Sg2, a Vizient company, is the health care industry’s trusted partner for accelerating growth and improving financial results. Our analytics and expertise help health care leaders achieve sustainable growth and maintain market relevance by optimizing System of CARE, payer and consumer strategies. Learn more at www.Sg2.com.

About Vizient, Inc.

Vizient, Inc., the nation’s largest provider-driven healthcare performance improvement company, serves more than 65% of the nation’s acute care providers, including 97% of the nation’s academic medical centers, and more than 35% of the non-acute market. The Vizient contract portfolio represents $140 billion in annual purchasing volume enabling the delivery of cost-effective, high-value care. With its acquisition of Kaufman Hall in 2024, Vizient expanded its advisory services to help providers achieve financial, strategic, clinical and operational excellence. Headquartered in Irving, Texas, Vizient has offices throughout the United States. Learn more at www.vizientinc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241114163229/en/